Complete with an assay that helps select eligible patients, the approved prostate-cancer (PC) drug Xtandi (enzalutamide) from Medivation Inc. and partner Astellas Pharma Inc. turned up hopeful phase II results in androgen-receptor (AR)-positive triple-negative breast cancer (TNBC), detailed at the recently concluded meeting of the American Society of Clinical Oncology in Chicago.